Log in

Aethlon Medical Stock Price, Forecast & Analysis (NASDAQ:AEMD)

-0.17 (-5.67 %)
(As of 11/22/2019 05:49 AM ET)
Today's Range
Now: $2.83
50-Day Range
MA: $2.92
52-Week Range
Now: $2.83
Volume4,000 shs
Average Volume16,762 shs
Market Capitalization$4.08 million
P/E RatioN/A
Dividend YieldN/A
Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:AEMD



Sales & Book Value

Annual Sales$230,000.00
Book Value$0.01 per share


Net Income$-6,200,000.00


Market Cap$4.08 million
Next Earnings Date2/10/2020 (Estimated)
OptionableNot Optionable

Receive AEMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AEMD and its competitors with MarketBeat's FREE daily newsletter.

Aethlon Medical (NASDAQ:AEMD) Frequently Asked Questions

What is Aethlon Medical's stock symbol?

Aethlon Medical trades on the NASDAQ under the ticker symbol "AEMD."

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) posted its quarterly earnings results on Monday, February, 11th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.04. View Aethlon Medical's Earnings History.

When is Aethlon Medical's next earnings date?

Aethlon Medical is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Aethlon Medical.

Has Aethlon Medical been receiving favorable news coverage?

Media stories about AEMD stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aethlon Medical earned a news impact score of -2.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Aethlon Medical.

Are investors shorting Aethlon Medical?

Aethlon Medical saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 7,500 shares, a drop of 48.3% from the September 30th total of 14,500 shares. Based on an average daily volume of 23,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.5% of the shares of the stock are short sold. View Aethlon Medical's Current Options Chain.

Who are some of Aethlon Medical's key competitors?

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Cytosorbents (CTSO), Novavax (NVAX), AT&T (T), NewLink Genetics (NLNK), Agile Therapeutics (AGRX), Ampliphi Biosciences (APHB), Ur-Energy (URG), Allena Pharmaceuticals (ALNA), Celldex Therapeutics (CLDX) and SCYNEXIS (SCYX).

Who are Aethlon Medical's key executives?

Aethlon Medical's management team includes the folowing people:
  • Mr. James B. Frakes, CFO, Sr. VP of Fin. & Sec. (Age 62)
  • Mr. James A. Joyce, Consultant (Age 57)
  • Dr. Timothy C. Rodell, Interim CEO & Director (Age 68)
  • Mr. Sunil Sawhney, Head of Clinical Studies
  • Dr. Richard H. Tullis, Consultant (Age 74)

Who are Aethlon Medical's major shareholders?

Aethlon Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cordasco Financial Network (1.02%).

Which major investors are buying Aethlon Medical stock?

AEMD stock was purchased by a variety of institutional investors in the last quarter, including Cordasco Financial Network.

How do I buy shares of Aethlon Medical?

Shares of AEMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aethlon Medical's stock price today?

One share of AEMD stock can currently be purchased for approximately $2.83.

How big of a company is Aethlon Medical?

Aethlon Medical has a market capitalization of $4.08 million and generates $230,000.00 in revenue each year. The medical equipment provider earns $-6,200,000.00 in net income (profit) each year or ($5.10) on an earnings per share basis. Aethlon Medical employs 6 workers across the globe.View Additional Information About Aethlon Medical.

What is Aethlon Medical's official website?

The official website for Aethlon Medical is http://www.aethlonmedical.com/.

How can I contact Aethlon Medical?

Aethlon Medical's mailing address is 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-459-7800 or via email at [email protected]

MarketBeat Community Rating for Aethlon Medical (NASDAQ AEMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Aethlon Medical and other stocks. Vote "Outperform" if you believe AEMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: What is the Quick Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel